INVITED RESEARCH HIGHLIGHT
Year : 2014  |  Volume : 16  |  Issue : 6  |  Page : 803-804

Further analysis of PREVAIL: Enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer


Department of Medicine, Division of Hematology and Oncology, George Washington University Medical Center, 2150 Pennsylvania Avenue, NW, Washington, DC 20037, USA

Correspondence Address:
Jeanny B Aragon-Ching
Department of Medicine, Division of Hematology and Oncology, George Washington University Medical Center, 2150 Pennsylvania Avenue, NW, Washington, DC 20037
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1008-682X.135129

Rights and Permissions

PREVAIL was a phase III multinational, double-blind, placebo-controlled trial that enrolled chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC), which showed remarkable improvement in co-primary endpoints with an overall 81% reduction in the risk of radiographic progression, as well as 29% reduction in the risk of death in favor of the enzalutamide arm over placebo. All secondary endpoints including time to subsequent chemotherapy initiation and prostate specific antigen (PSA) progression were in favor of the enzalutamide arm. The results of PREVAIL shows the utility of enzalutamide that would likely soon expand the indication to asymptomatic or minimally symptomatic men with mCRPC not previously treated with chemotherapy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2067    
    Printed42    
    Emailed1    
    PDF Downloaded833    
    Comments [Add]    
    Cited by others 1    

Recommend this journal